%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2019-10-14T10:58:12-04:00
2019-10-14T10:58:17-04:00
2019-10-14T10:58:17-04:00
Adobe InDesign CC 13.1 (Windows)
uuid:cd8d207c-9b91-4b19-9aa9-67b90003397e
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:2d7d5224-3878-834f-866a-af4fad5086ad
proof:pdf
xmp.iid:a66f4790-8c3b-9a41-a534-e7f1fef5c7ea
xmp.did:26167800-531c-694f-a788-b693d10f6672
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 13.1 (Windows)
/
2019-10-14T10:58:12-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
12 0 obj
<>
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
68 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8.5 0 0 8.5 173.0087 533.5704 Tm
(1.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(A large observational study of hypertension)-10 ( )]TJ
0 -1.2 Td
[(treatment to < 140/90 mmHg in older patients)-10 ( )]TJ
0 -1.2 Td
(showed that mortality was highest in:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
(a. patients 70-79 years of age.)Tj
0 -1.2 Td
(b. patients > age 80 years.)Tj
0 -1.2 Td
(c. patients with no prior heart disease.)Tj
0 -1.2 Td
[(d. patients with systolic blood pressure)-10 ( )]TJ
0 Tc 16.651 0 Td
( )Tj
-0.01 Tc -16.651 -1.2 Td
(< 160 mmHg.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-1.588 -2.894 Td
(2.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(In the Jack et al study of the associations of)-9.9 ( )]TJ
0 -1.2 Td
[(amyloid \(A\), tau \(T\), and neurodegeneration)-10 ( )]TJ
0 -1.2 Td
[(\(N\) biomarker pro\037les in individuals without)-10 ( )]TJ
0 -1.2 Td
(dementia, which was true?)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
[(a. Addition of A)74 (T\(N\) biomarker pro\037le to)-10 ( )]TJ
0 -1.2 Td
[(a traditional clinical prediction model led)-10 ( )]TJ
0 -1.2 Td
[(only to a modest, statistically insigni\037cant)-10 ( )]TJ
0 -1.2 Td
[(improvement in the prediction of memory)-10 ( )]TJ
0.01 Tw 0 -1.2 Td
(decline.)Tj
0 Tw 0 -1.2 Td
[(b. Individuals with the worst pathological)-10 ( )]TJ
0 -1.2 Td
[(changes A+T+\(N+\), A+T+\(N-\), A+T)104 (-N\(+\))-10 ( )]TJ
0 -1.2 Td
(experienced the fastest rate of memory decline.)Tj
22.896 24.494 Td
[(c. Age and APOE E4 status were not)-10 ( )]TJ
0 -1.2 Td
(associated with faster rate of memory decline.)Tj
0 -1.2 Td
[(d. Approximately 90% of memory decline)-10 ( )]TJ
0 -1.2 Td
[(with older age was associated with abnormal)-10 ( )]TJ
0 -1.2 Td
[(A)74 (T\(N\) biomarker pro\037le in predementia)-10 ( )]TJ
0.01 Tw 0 -1.2 Td
(individuals.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
0 Tw -1.588 -2.894 Td
(3.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(Direct oral anticoagulants have no advantages)-10 ( )]TJ
0 -1.2 Td
(over oral vitamin K antagonists \(warfarin\).)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
[(a. T)67 (rue)]TJ
0 -1.2 Td
(b. False)Tj
ET
endstream
endobj
69 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 cs 0.07 scn
/GS0 gs
18 190.08 120.33 565.92 re
f
18 36 539.325 53.473 re
f
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 7 0 0 7 27.8983 78.3659 Tm
(Interested in reprints or posting an article to your )Tj
0 -1.143 Td
[(company)-55.8 (\222s site? There are numerous opportunities for )]TJ
0 -1.143 Td
(you to leverage editorial recognition for the benefit of )Tj
0 -1.143 Td
(your brand. Call us at \(800\) 688-2421 or email us at )Tj
0 -1.143 Td
(reprints@reliasmedia.com.)Tj
25.217 4.571 Td
(Discounts are available for group subscriptions, multiple )Tj
0 -1.143 Td
(copies, site licenses, or electronic distribution. For pricing )Tj
0 -1.143 Td
(information, please contact our Group Account Managers )Tj
0 -1.143 Td
(at groups@reliasmedia.com or \(866\) 213-0844.)Tj
19.248 0 Td
( )Tj
5.969 3.429 Td
[(T)175 (o reproduce any part of R)17.6 (elias Media newsletters for )]TJ
0 -1.143 Td
(educational purposes, please contact The Copyright )Tj
0 -1.143 Td
(Clearance Center for permission at info@copyright.com )Tj
0 -1.143 Td
(or \(978\) 750-8400.)Tj
ET
/CS0 CS 1 SCN
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 138.6633 754.5 cm
0 0 m
437.337 0 l
S
Q
/CS0 cs 1 scn
163.266 260.54 392.225 16.326 re
f
BT
0 scn
0.041 Tc -0.016 Tw 10 0 0 10 319.6411 265.021 Tm
[(CM)1 (E)16 ( O)4.1 (B)11.9 (J)2.4 (E)24.3 (C)-1.4 (T)14.1 (I)0.5 (VE)9.9 (S)]TJ
ET
1 scn
165.309 551.709 392.414 18.174 re
f
0.25 w
165.372 313.401 392.225 238.183 re
S
BT
0 scn
0.037 Tc -0.012 Tw 10 0 0 10 320.7545 557.9383 Tm
[(C)-3.7 (M)-3 (E)12 ( Q)1.9 (U)-3.3 (E)5.9 (S)4.8 (T)10.1 (ION)-11.3 (S)]TJ
ET
0.07 scn
164.457 609.559 392.475 117.38 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
-0.02 Tc 0 Tw 9 0 0 9 172.4189 711.5055 Tm
[(T)174.8 (o earn credit for this activity)87 (, please follow these instructions:)]TJ
0 Tc 22.102 0 Td
( )Tj
-0.02 Tc -22.102 -1.222 Td
[(1. R)17.5 (ead and study the activity)87 (, using the provided references for further research.)]TJ
0 Tc 29.127 0 Td
( )Tj
-0.02 Tc -29.127 -1.222 Td
[(2. L)17.4 (og on to )]TJ
/TT0 1 Tf
0.02 Tw [(R)17.6 (eliasMedia.com)]TJ
/TT1 1 Tf
0 Tw [( and click on My Account. F)35.9 (irst-time users must register on the site. T)174.8 (ests are taken)-19.9 ( )]TJ
0 -1.222 Td
(after each issue.)Tj
0 Tc 5.741 0 Td
( )Tj
-0.02 Tc -5.741 -1.222 Td
[(3. P)54.7 (ass the online test with a score of 100%; you will be allowed to answer \
the questions as many times as needed)-20.3 ( )]TJ
0 -1.222 Td
[(to achieve a score of 100%.)-20 ( )]TJ
0 Tc 10.468 0 Td
( )Tj
-0.02 Tc -10.468 -1.222 Td
[(4. After successfully completing the test, your browser will be automati\
cally directed to the activity evaluation form,)-19.9 ( )]TJ
0 -1.222 Td
(which you will submit online.)Tj
0 -1.222 Td
(5. Once the completed evaluation is received, a credit letter will be em\
ailed to you.)Tj
ET
/CS0 cs 1 scn
/GS0 gs
163.266 727 393.666 17.367 re
f
BT
0 scn
/TT0 1 Tf
0.037 Tc -0.012 Tw 10 0 0 10 295.1102 732.5228 Tm
[(C)-3.7 (M)-3 (E)12 ( I)-1.3 (N)-11.4 (S)4.8 (T)7.7 (R)6.1 (U)2.7 (C)-5.3 (T)10.1 (ION)-11.3 (S)]TJ
1 scn
0.01 Tc 0 Tw 9 0 0 9 163.2662 249.7026 Tm
[(Upon completion of this educational activity)87.1 (, participants should be able to:)]TJ
ET
18 106.402 539.325 58.612 re
f
BT
0 0 0 0 k
/T1_0 1 Tf
0.057 Tc -0.032 Tw 18 0 0 18 28.84 141.6379 Tm
[([)8.9 (I)-2.2 (N)32 ( FU)-7.2 (T)-9.2 (UR)0.5 (E)57 ( )]TJ
0 Tc 0 Tw 6.562 0 Td
( )Tj
0.013 Tc -0.013 Tw -6.562 -1.2 Td
[(I)-21.9 (S)-23.9 (S)-14.3 (U)-46.2 (E)-36.6 (S])]TJ
/TT0 1 Tf
0 Tc 0 Tw 3.719 0 Td
( )Tj
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
6 0 0 6 25.2 744.168 Tm
(PHYSICIAN EDITOR)Tj
/TT0 1 Tf
0 -1.167 Td
(Stephen A. Brunton, MD)Tj
/TT1 1 Tf
-0.025 Tc 0 -1.167 Td
[(Adjunct P)35.6 (rofessor of Pharmacy P)35.7 (ractice)]TJ
0 -1.167 Td
(College of Pharmacy)Tj
0 Tc 7.469 0 Td
( )Tj
-0.025 Tc -7.469 -1.167 Td
[(R)17.5 (oseman University of Health Sciences)]TJ
0 Tc 13.998 0 Td
( )Tj
-0.025 Tc -13.998 -1.167 Td
[(Salt L)17.4 (ake City)]TJ
/T1_0 1 Tf
0 Tc 0 -2.667 Td
(PEER REVIEWER)Tj
/TT0 1 Tf
0 -1.167 Td
[(Gerald R)17.7 (oberts, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
(Senior Attending Physician )Tj
( )Tj
0 -1.167 Td
[(L)17.4 (ong Island Jewish Medical Center)]TJ
13.107 0 Td
( )Tj
-13.107 -1.167 Td
(NS/LIJ Health Care System)Tj
10.378 0 Td
( )Tj
-10.378 -1.167 Td
[(New Hyde P)54.8 (ark, NY)]TJ
/T1_0 1 Tf
0 -2.333 Td
[(EDITORIAL ADVISOR)92.1 (Y BOARD)]TJ
/TT0 1 Tf
0 -1.167 Td
(James Chan, PharmD, PhD)Tj
/TT1 1 Tf
0 -1.167 Td
[(Associate Clinical P)34.4 (rofessor)]TJ
( )Tj
0 -1.167 Td
(School of Pharmacy)Tj
7.563 0 Td
( )Tj
-7.563 -1.167 Td
[(University of California, San F)54 (rancisco)]TJ
/TT0 1 Tf
0 -1.917 Td
[(William T)156.1 (. Elliott, MD, F)36.2 (A)17.5 (CP)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Assistant Clinical P)33.9 (rofessor of Medicine )]TJ
0 -1.167 Td
[(University of California, San F)54 (rancisco)]TJ
/TT0 1 Tf
0 -2.333 Td
(David Fiore, MD)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor of F)35.9 (amily Medicine)]TJ
0 -1.167 Td
[(University of Nevada, R)17.1 (eno)]TJ
/TT0 1 Tf
0 -1.917 Td
[(K)17.7 (en Grauer)100.9 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor Emeritus in F)35.1 (amily )]TJ
( )Tj
0 -1.167 Td
(Medicine, College of Medicine,)Tj
0 -1.167 Td
(University of Florida)Tj
/TT0 1 Tf
0 -2.333 Td
(Seema Gupta, MD, MSPH)Tj
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor)100.4 (,)]TJ
0 -1.167 Td
[(Department of F)35.5 (amily and Community)]TJ
0 -1.167 Td
(Health, Joan C. Edwards School of Medicine)Tj
0 -1.167 Td
(Marshall University)Tj
0 -1.167 Td
(Huntington, WV)Tj
/TT0 1 Tf
-0.01 Tc 0 -1.917 Td
[(Harold L. K)17.8 (arpman, MD, F)35.8 (A)17.5 (CC, F)35.7 (A)17.6 (CP)]TJ
/TT1 1 Tf
-0.03 Tc 0 -1.167 Td
[(Clinical P)35.7 (rofessor of Medicine)]TJ
0 Tc 10.349 0 Td
( )Tj
-0.03 Tc -10.349 -1.167 Td
(David Geffen School of Medicine at UCLA)Tj
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Louis K)17.8 (uritzky)87.5 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor)100.4 (, )]TJ
0 -1.167 Td
(University of Florida, Gainesville)Tj
/TT0 1 Tf
0 -1.917 Td
[(Martin S. Lipsky)87.5 (, MD)]TJ
/TT1 1 Tf
-0.03 Tc 0 -1.167 Td
[(Chancellor)100.5 (, South Jordan Campus, R)17.5 (oseman)-29.9 ( )]TJ
0 -1.167 Td
(University of Health Sciences, South Jordan, UT)Tj
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Joseph E. Scherger)101.6 (, MD, MPH)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Core F)35.8 (aculty)86.9 (,)]TJ
0 -1.167 Td
[(Eisenhower Health F)35.5 (amily Medicine R)16.7 (esidency )]TJ
0 -1.167 Td
[(P)35.7 (rogram,)]TJ
0 -1.167 Td
[(Eisenhower Health Center)99.9 (, L)17.5 (a Quinta, CA)-18.8 (;)]TJ
0 -1.167 Td
[(Clinical P)34.8 (rofessor)100.4 (,)]TJ
0 -1.167 Td
[(K)17.6 (eck School of Medicine,)]TJ
0 -1.167 Td
[(University of Southern California, L)16.8 (os Angeles)]TJ
/TT0 1 Tf
0 -1.917 Td
(Allan J. Wilke, MD, MA)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor and Chair)]TJ
7.542 0 Td
( )Tj
-7.542 -1.167 Td
[(Department of F)35.5 (amily Medicine)]TJ
12.045 0 Td
( )Tj
-12.045 -1.167 Td
[(W)54.9 (estern Michigan University)]TJ
10.92 0 Td
( )Tj
-10.92 -1.167 Td
[(School of Medicine, K)17.8 (alamazoo)]TJ
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jonathan Springston)Tj
/T1_0 1 Tf
0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jason Schneider)Tj
/T1_0 1 Tf
0 -2.5 Td
(EDITORIAL GROUP MANAGER)Tj
/TT0 1 Tf
0 -1.333 Td
(Leslie Coplin)Tj
/T1_0 1 Tf
0 -2.667 Td
[(ACCREDIT)74 (A)74 (TIONS MANAGER)]TJ
/TT0 1 Tf
0 -1.25 Td
(Amy M. Johnson, MSN, RN, CPN)Tj
/CS0 cs 1 scn
/GS0 gs
/TT1 1 Tf
0.01 Tc 9 0 0 9 163.2662 237.1787 Tm
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(describe new findings in the differential diagnosis and treatment of var\
ious diseases;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
[(describe the advantages, disadvantages, and controversies surrounding th\
e latest advances in the diagnosis)9.8 ( )]TJ
/Span<>> BDC
-1.111 -1.222 Td
[( )-238 ( )]TJ
EMC
1.111 0 Td
(and treatment of disease;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(identify cost-effective treatment regimens;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(explain the advantages and disadvantages of new disease screening proced\
ures.)Tj
0 0 0 0 k
0 Tc -0.985 -5.614 Td
(Is It Safe to Stop Digoxin )Tj
( )Tj
0 -1.2 Td
[(for Heart F)35.6 (ailure?)]TJ
22.038 1.2 Td
[(Effects of P)35.4 (robiotics on Cognition and F)35.6 (all Risk )]TJ
17.685 0 Td
( )Tj
-17.685 -1.2 Td
[(in P)54.7 (atients W)17.1 (ith Cirrhosis)]TJ
ET
endstream
endobj
70 0 obj
<>
endobj
71 0 obj
<>
endobj
72 0 obj
<>
endobj
77 0 obj
<>
endobj
78 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
79 0 obj
<>stream
HtV TSW[#k
aQ+h":"kXnUKkPGŌZ8jbZ+2Jdii?9}=0 X)Nm'ɹ%EQ *5j@XI:PP<|#@$w
,{%{2y- @WH
,`HTXRYp )rNYn竀 ή$ ";הf6JAvPVQiwv|~/$0c:p_ }+q^q, (p~K*@"4O8ɍXݨZ1/" JZy$+;8:9+U.nꁞ^>~@/ 6<~ȄQ/N|)1c_7~IjʔԩZ3_Ϝܼ|}AaQ9%eUW/xͅ/Yֲ+ޮ]jw]n?ܺmv?OrO[>;#;z'N~qg~u|ۅ͕߸y:wB h `a2S1ŒTͪ";'4HMC@`8$p\`~й'b!v090?^b,bR
[+b@g[lbP,%EӒI˖"=ﯸ?تW~op`83c?w>Qamkb˱ǰm5؆hոe؈no`jo0vb1ug 8B}##!~.@'npq8-§8M[ۃz?6OG
Xm{'pQG _׃Tjc9{BOl
(bP/4#$
h$T:/ X
pMS~l9,zfYdI>Y!ykQ¥`,?JLȑC\,rA&oqʛZ+/ֲIrU4jinb\:&BZ;:A<$ g#j>ʲS !TB5Ɏ2tioՈ'|:|E4]TAi֙dLg,1iF.h|1qJ߈1"@sbIIF)BaS5cJ&tbI?&9kyL$<)\.OE)
vS)U
PV]ͲJ$gkDgLo)H@Ez"]hvY蟳z=.Xy|9;%gqYA$wLw7,.NL΅Zr,b3o{ծE,|}<n.* /MQn7Uמ`H?luѰ WݹqP3s66$|6ϼ`4w,m6g)y->瘿f'mv0ava2X76o/fH\%
_E
C@@"#<09dW5H^
p<%/>JkjmW'uǪxU1t7ʃC<W ;($%PpЎk%tf+\+܇V}HJrL\ΊC,h{6a^UCCUUcLvG5y^yޏ&y #ΨD d~!ZVdCH5SQd"1=VnmNZCUOi jOONx?{{w^X+ZW\V~2_^zGM˕+7w///_f(;Gs)ȉ~vf8:DKL
'iVEIQvޙ3dÙ,0!9^0%1L`.>A,cP&*583ӕ.s0.-{u5JVHmxŏ^rhvLn;'`;>۹hq2RԻhVKW|E~TaN)*W+B7ZC"+=`ïsiPcUi8sapxf0-pߠD^E?zz>h}@C04QۨFd3#ۦLbK`M83\O959Ng~q/-ԝӆ2O^7
>!K84aL@Pò)9UXrځM-Qp
.&&$
΄_OF\G'/LFb#N6Lp-gF?mBM&Mhj1H
1P Tn8ǗsT:Vb2WGR}/H*S?G
zjDSwQ[CHT`$otˑtj{]ކ"VCfb
Ϛ!w'Z "U`SVzC[+`\#ru%<`9qgn=ZO*M}K